Ticker Hub
ALLO — AI Analysis & Sentiment
3 recent AI-generated analyses for ALLO. Sentiment and confidence insights updated continuously.
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported encouraging interim Phase 2 data for Cema-Cel in LBCL and extended its cash runway to Q1 2029. These updates de-risk...
May 13, 2026Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics received regulatory clearance for its pivotal Phase 2 ALPHA3 trial in South Korea and Australia, enabling broader enrollment ...
Apr 21, 2026Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
The closing of Allogene's $200.4 million public offering provides critical capital, extending its cash runway. This financial stability is crucial ...
Apr 16, 2026